HO902DLBCL: A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients

Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04139252
Collaborator
(none)
250
60
38.5
4.2
0.1

Study Details

Study Description

Brief Summary

Observational prospective study. Patients with DLBCL and HGBCL will be enrolled in the study to collect samples for developing a blood based assay allowing biomarker driven treatment in the future.

Condition or Disease Intervention/Treatment Phase
  • Other: No intervention

Detailed Description

The rationale of this study is that, due to the lack of successful salvage options, first-line treatment outcome needs to be improved. To make this possible, a crucial condition is optimal identification of patients that will not be cured on R-CHOP. The aim of this protocol is to develop new tools to monitor treatment response and disease outcome. Molecular monitoring of treatment response through liquid biopsies (LB) is such a promising new tool.

The primary objective is to collect liquid biopsy samples of patients with newly diagnosed DLBCL/HGBCL to develop a blood based assay allowing biomarker driven treatment in the future.

The secondary objectives are to collect clinical data and pre-treatment tissue samples (for determining molecular profiles) to allow for correlation to the blood based assay.

This study is designed for patients with newly diagnosed DLBCL and HGBCL ≥ 18 yr.

Study Design

Study Type:
Observational
Actual Enrollment :
250 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A National Study for Blood Based Response Monitoring of Newly Diagnosed Aggressive B-cell Lymphoma (DLBCL and HGBCL) Patients
Actual Study Start Date :
Mar 17, 2020
Anticipated Primary Completion Date :
Jun 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Tissue material [24 months]

    For genomic analysis and clinical outcome data

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with newly diagnosed DLBCL (including HGBCL- NOS and HGBCL-DH) according to WHO classification 2016

  • Ann Arbor stage II-IV

  • Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible)

  • Age ≥ 18 years

Exclusion Criteria:
  • Patients with limited stage I, II disease planned to receive 3 cycles of R-CHOP + radiotherapy, or 4 x R-CHOP+ 2R

Contacts and Locations

Locations

Site City State Country Postal Code
1 NL-Alkmaar-NWZ Alkmaar Netherlands
2 NL-Almelo-ZGTALMELO Almelo Netherlands
3 NL-Almere-FLEVOZIEKENHUIS Almere Netherlands
4 NL-Amersfoort-MEANDERMC Amersfoort Netherlands
5 NL-Amstelveen-AMSTELLAND Amstelveen Netherlands
6 NL-Amsterdam-AMC Amsterdam Netherlands
7 NL-Amsterdam-OLVG Amsterdam Netherlands
8 NL-Amsterdam-VUMC Amsterdam Netherlands
9 NL-Arnhem-RIJNSTATE Arnhem Netherlands
10 NL-Assen-WZA Assen Netherlands
11 NL-Beverwijk-RKZ Beverwijk Netherlands
12 NL-Breda-AMPHIA Breda Netherlands
13 NL-Capelle a/d IJssel-YSL Capelle Aan Den IJssel Netherlands
14 NL-Delft-RDGG Delft Netherlands
15 NL-Den Bosch-JBZ Den Bosch Netherlands
16 NL-Den Haag-HAGA Den Haag Netherlands
17 NL-Den Haag-HMCWESTEINDE Den Haag Netherlands
18 NL-Deventer-DZ Deventer Netherlands
19 NL-Dirksland-VANWEELBETHESDA Dirksland Netherlands
20 NL-Doetinchem-SLINGELAND Doetinchem Netherlands
21 NL-Dordrecht-ASZ Dordrecht Netherlands
22 NL-Ede-ZGV Ede Netherlands
23 NL-Eindhoven-CATHARINA Eindhoven Netherlands
24 NL-Eindhoven-MAXIMAMC Eindhoven Netherlands
25 NL-Emmen-SCHEPER Emmen Netherlands
26 NL-Enschede-MST Enschede Netherlands
27 NL-Geldrop-STANNA Geldrop Netherlands
28 NL-Goes-ADRZ Goes Netherlands
29 NL-Gorinchem-BEATRIX Gorinchem Netherlands
30 NL-Gouda-GROENEHART Gouda Netherlands
31 NL-Groningen-UMCG Groningen Netherlands
32 NL-Hardenberg-SAXENBURGH Hardenberg Netherlands
33 NL-Harderwijk-STJANSDALHARDERWIJK Harderwijk Netherlands
34 NL-Heerenveen-TJONGERSCHANS Heerenveen Netherlands
35 NL-Helmond-ELKERLIEK Helmond Netherlands
36 NL-Hoofddorp-SPAARNEGASTHUIS Hoofddorp Netherlands
37 NL-Hoorn-DIJKLANDERHOORN Hoorn Netherlands
38 NL-Leeuwarden-MCL Leeuwarden Netherlands
39 NL-Leiden-LUMC Leiden Netherlands
40 NL-Maastricht-MUMC Maastricht Netherlands
41 NL-Nieuwegein-ANTONIUS Nieuwegein Netherlands
42 NL-Nijmegen-CWZ Nijmegen Netherlands
43 NL-Roermond-LZR Roermond Netherlands
44 NL-Roosendaal-BRAVIS Roosendaal Netherlands
45 NL-Rotterdam-ERASMUSMC Rotterdam Netherlands
46 NL-Rotterdam-IKAZIA Rotterdam Netherlands
47 NL-Rotterdam-MAASSTADZIEKENHUIS Rotterdam Netherlands
48 NL-Rotterdam-SFG Rotterdam Netherlands
49 NL-Sneek-ANTONIUSSNEEK Sneek Netherlands
50 NL-Spijkenisse-SPIJKENISSEMC Spijkenisse Netherlands
51 NL-Terneuzen-ZORGSAAM Terneuzen Netherlands
52 NL-Tiel-RIVIERENLAND Tiel Netherlands
53 NL-Tilburg-ETZ Tilburg Netherlands
54 NL-Uden-BERNHOVEN Uden Netherlands
55 NL-Utrecht-DIAKONESSENUTRECHT Utrecht Netherlands
56 NL-Utrecht-UMCUTRECHT Utrecht Netherlands
57 NL-Venlo-VIECURI Venlo Netherlands
58 NL-Winterswijk-SKBWINTERSWIJK Winterswijk Netherlands
59 NL-Zutphen-GELREZUTPHEN Zutphen Netherlands
60 NL-Zwolle-ISALA Zwolle Netherlands

Sponsors and Collaborators

  • Stichting Hemato-Oncologie voor Volwassenen Nederland

Investigators

  • Principal Investigator: M.E.D. Chamuleau, MD, PhD, VUmc

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Stichting Hemato-Oncologie voor Volwassenen Nederland
ClinicalTrials.gov Identifier:
NCT04139252
Other Study ID Numbers:
  • HO902
First Posted:
Oct 25, 2019
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Mar 23, 2022